Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683617 | 0.91 | CHRM2 (0.51) | MAPK1LMNACHRM2HTR1ACHRM1 | |
| Flufylline SCHEMBL684324 | 0.90 | HTR2A (0.60) | LMNACHRM2HTR1ACHRM1DRD2 | |
| SCHEMBL683965 | 0.88 | LMNA (0.58) | MAPK1LMNACHRM2HTR1ACHRM1 | |
| SCHEMBL684325 | 0.85 | CHRM2 (0.49) | MAPK1LMNACHRM2HTR1ACHRM1 | |
| Fluprofylline SCHEMBL683614 | 0.85 | HTR1A (0.64) | MAPK1CHRM2HTR1ACHRM1DRD2 | |
| Perbufylline SCHEMBL682795 | 0.85 | HTR1A (0.61) | MAPK1CHRM2HTR1ACHRM1DRD2 | |
| SCHEMBL10721910 | 0.84 | HTR1A (0.60) | MAPK1CHRM2HTR1ACHRM1DRD2 | |
| SCHEMBL683633 | 0.81 | CHRM2 (0.51) | MAPK1LMNACHRM2HTR1ACHRM1 | |
| SCHEMBL683632 | 0.81 | CHRM2 (0.51) | MAPK1LMNACHRM2HTR1ACHRM1 | |
| SCHEMBL682797 | 0.81 | ALDH1A1 (0.60) | MAPK1LMNACHRM2HTR1ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | MAPK1 470/4885LMNA 2155/4885CHRM2 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.